MIC
IBB icon

Meridian Investment Counsel’s iShares Biotechnology ETF IBB Stock Holding History

Meridian Investment Counsel’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Hold
2,734
– – 0.11% 161
2026
Q1 		$462K Buy
2,734
+59
+2% +$10.1K 0.11% 165
2025
Q4 		$451K Buy
2,675
+290
+12% +$47.1K 0.11% 162
2025
Q3 		$344K Buy
+2,385
New +$326K 0.09% 179

Other funds holding IBB

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Meridian Investment Counsel's IBB Position: Q2 2026 in Review

Meridian Investment Counsel held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2,734 shares worth $520K. The position accounts for 0.11% of the portfolio, ranked #161.

Meridian Investment Counsel first reported a position in IBB in Q3 2025 and has held it in 4 quarters since. 758 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Meridian Investment Counsel held 2,734 shares of iShares Biotechnology ETF worth $520K as of Q2 2026.
  • Meridian Investment Counsel left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up 0.11% of Meridian Investment Counsel's portfolio in Q2 2026, its #161 holding.
  • Meridian Investment Counsel first reported a position in iShares Biotechnology ETF in Q3 2025 and has held it in 4 quarters since.
  • 758 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Meridian Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.